Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Biotechnology

Healthcare
$8.56 +0.66%

+$0.13 today

Market cap
$770.64M
Beta
0.39
P/E (TTM)
-6.8
EPS (TTM)
-$2.81
52W Low $8.59High $25.59

Volume 3.46M

Average 1.70M

SNDX Income Before Tax

Profit after all operating and non-operating items but before income tax.

Syndax Pharmaceuticals, Inc.NASDAQ: SNDX

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$42.67M, compared with -$84.85M a year earlier. Trailing-twelve-month income before tax was -$243.25M.

Context

  • Income before tax amounted to 165.6% of revenue in FY2025, down 1180.5 pp from a year earlier.
  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$42.67M or moves back toward the trailing-twelve-month quarterly average of -$60.81M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$42.67M+37.3% QoQ
Last fiscal yearDec 2025
-$285.42M+10.5% YoY
LTMMar 2026
-$243.25M+26.6% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+49.7%——
1 year+10.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(285.42M) USD
Year-over-year change
+10.5%

Income Before Tax vs competitors

How SNDX compares with its peers on the latest reported figures

  • SNDX's LTM Mar 2026 income before tax of -$243.25M is the 9th highest of the 11 companies compared; the peer median is -$112.04M.
  • Its year-over-year change of +26.6% is the 4th highest of 11, against a peer median of +4.3%.
  • Income before tax amounts to 112.0% of revenue for SNDX, versus a peer median of 88.2%.
SNDX Competitors Peer median
Income Before Tax for SNDX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$308.21M +226.3%—43.9%
ZYMEZymeworks Inc.LTM Sep 2026$40.12M +171.6%—15.1%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-$58.91M -240.8%—165.7%
MGNXMacroGenics, Inc.LTM Mar 2026-$71.03M -29.5%—45.2%
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$88.87M +31.7%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$135.21M -1.8%——
NUVBNuvation Bio Inc.LTM Jun 2026-$149.83M +26.2%—88.2%
XNCRXencor, Inc.LTM Jun 2026-$160.85M +10.3%—153.2%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-$243.25M +26.6%—112.0%
REPLReplimune Group, Inc.LTM Dec 2025-$315.82M -38.7%——
RCUSArcus Biosciences, Inc.LTM Jun 2026-$452M -47.7%—386.3%
Peer median (excluding SNDX) -$112.04M+4.3%—88.2%

Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue139.71M0023.68M172.35M
Cost of Revenue000826K6.97M
Gross Profit139.71M0022.85M165.38M
Gross Margin100.0%——96.5%96.0%
Research & Development88.25M118.5M163.03M241.65M258.78M
Selling, General & Admin25.24M33.26M66.92M120.88M179.68M
Operating Expenses113.49M151.76M229.95M362.53M438.47M
Depreciation & Amortization43K33K12K8K6K
EBITDA26.87M(146.17M)(209.14M)(313.82M)(251.63M)
EBITDA Margin19.2%——-1325.3%-146.0%
Operating Income26.22M(151.76M)(229.95M)(339.67M)(273.08M)
Operating Margin18.8%——-1434.4%-158.4%
Interest Income403K5.87M21.16M26.09M22.73M
Interest Expense1.9M3.14M208K4.93M33.79M
Other Income / Expenses(1.29M)2.42M20.59M20.91M(12.34M)
Income Before Tax24.93M(149.34M)(209.36M)(318.76M)(285.42M)
Pre-Tax Margin17.8%——-1346.1%-165.6%
Income Tax Expense00000
Net Income24.93M(149.34M)(209.36M)(318.76M)(285.42M)
Net Margin17.8%——-1346.1%-165.6%
EPS (Basic)0.48(2.46)(2.98)(3.73)(3.29)
EPS (Diluted)0.48(2.46)(2.98)(3.73)(3.29)
Weighted Avg Shares52.06M60.76M70.37M85.62M86.63M
Weighted Avg Shares (Diluted)52.06M60.76M70.37M85.62M86.63M

Syndax Pharmaceuticals, Inc.

NASDAQ:SNDX

Intrinsic Alpha fair value

Locked

Current Price

$8.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.